AMAG Pharmaceuticals has developed a microfluidic chip-based assay device for measuring clotting times in blood samples without the need for chemical activating agents. The device utilizes anionically charged surfaces to activate clotting and integrated electrodes to measure changes in electrical impedance, allowing for precise and reproducible clot formation analysis. GlobalData’s report on AMAG Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights AMAG Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on AMAG Pharmaceuticals, was a key innovation area identified from patents. AMAG Pharmaceuticals's grant share as of February 2024 was 30%. Grant share is based on the ratio of number of grants to total number of patents.

Microchip for measuring clotting time in blood samples

Source: United States Patent and Trademark Office (USPTO). Credit: AMAG Pharmaceuticals Inc

A recently granted patent (Publication Number: US11852639B2) discloses a test microchip designed for measuring clotting time in blood or plasma samples. The microchip features microchannels with test chambers that draw samples through capillary action, activating clotting upon entry due to anionically charged surfaces. Integrated electrodes within the microchip measure changes in electrical impedance to determine clot formation accurately. The patent also includes a microassay device incorporating the test microchip and a reader, where the reader detects impedance changes and regulates temperature to provide precise clotting time measurements.

Furthermore, the patent outlines a method for measuring clotting time using the test microchip and reader system. By applying a blood or plasma sample to the microchip within the reader, changes in electrical impedance are monitored to determine clotting time accurately. The method involves regulating the temperature of the test chamber and obtaining output data on the clotting time, with the change in impedance measured by applying an AC voltage to the sample. This innovative technology offers a reliable and efficient solution for measuring clotting time in blood or plasma samples, with potential applications in various medical and diagnostic settings.

To know more about GlobalData’s detailed insights on AMAG Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies